The common side effects such as nausea, joint pain, and fatigue during Elacestrant treatment can be effectively controlled through a graded management strategy. The following provides specific management plans from four aspects: symptom characteristics, intervention measures, medical indications, and contraindications for medication.

1. Nausea management

(1) Mild nausea can be adjusted to take medication before bedtime;

(2) Eat light food in small portions in batches;

(3) Avoid high-fat/spicy foods;

(4) Severe nausea requires consideration of dosage adjustment.

Joint pain management

(1) Gentle hot compress to relieve symptoms;

(2) Low intensity stretching exercise;

(3) Avoid excessive weight-bearing on joints;

(4) Continuous pain requires evaluation of inflammatory markers.

3 Fatigue coping strategies

(1) Maintain a regular daily routine;

(2) Moderate daytime activity;

(3) Supplementing with iron/vitamin D;

(4) Hemoglobin levels below 8g/dL require medical attention.

Principle of 4-level processing

(1) Level 1: Maintenance dose+symptomatic treatment;

(2) Level 2: Temporary interruption;

(3) Level 3: Interrupt and reduce volume;

(4) Level 4: Permanent discontinuation of medication.

5 Emergency Medical Indications

(1) Vomiting accompanied by dehydration;

(2) Joint redness, swelling, heat and pain;

(3) Extreme fatigue accompanied by blurred consciousness;

(4) The symptoms continue to worsen.

6 patients with severe liver function impairment

Ailasetran is contraindicated in patients with Child Pugh C liver dysfunction. Patients with moderate liver function impairment (Child Pugh B) need to reduce the dose to 258mg, while mild impairment (Child Pugh A) does not require dose adjustment.

Pregnant women are prohibited from using 7

Based on animal studies, Ailasequn can cause fetal malformations and is absolutely contraindicated for pregnant women. Women of childbearing age need to confirm their pregnancy status before taking medication, and effective contraceptive measures should be taken during treatment and one week after discontinuing medication.

8 lactating women

Lack of data on the excretion of Ailasetran in breast milk, breastfeeding should be stopped during treatment and within one week after discontinuation. It is necessary to weigh the benefits of treatment against potential infant risks.